Sheer and colleagues reviewed electronic health record data from 26,408 adults treated in the OneFlorida+ network from 2014 to 2024, covering 14 healthcare organizations across Florida, Georgia, and Alabama
There are currently four popular GLP-1 agonists approved by the FDA (two FDA-approved agonists, lixisenatide and exenatide, have been discontinued in recent years)
All meds are In-Stock
Injection site rotation prevents lipodystrophy (fat tissue changes at overused sites)
These medications are transforming the treatment landscape, dramatically improving the amount of weight loss achievable through medication alone or in combination with lifestyle interventions, shared Miranda Stiewig-Rapp, assistant professor of endocrinology at UC Davis Health
Where this is headed GLP-1s arent going away